Share This Page
RYSTIGGO Drug Profile
✉ Email this page to a colleague
Summary for Tradename: RYSTIGGO
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
Pharmacology for RYSTIGGO
| Mechanism of Action | Neonatal Fc Receptor Blockers |
| Established Pharmacologic Class | Neonatal Fc Receptor Blocker |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for RYSTIGGO Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for RYSTIGGO Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for RYSTIGGO Derived from Patent Text Search
No patents found based on company disclosures
Rystiggo Market Dynamics, Revenue Trajectory, Patents and Competitive Outlook
Rystiggo, UCB’s rozanolixizumab-noli, is an anti-neonatal Fc receptor biologic approved for adults with generalized myasthenia gravis, or gMG. Its commercial trajectory depends on repeat treatment cycles, expansion beyond the initial U.S. indication, payer acceptance, and competition from Vyvgart, Vyvgart Hytrulo, Soliris, Ultomiris and emerging FcRn therapies.
UCB reported Rystiggo net sales of approximately €14 million in 2023 and approximately €174 million in 2024. The product remains in the early commercial ramp phase, with revenue growth driven primarily by U.S. adoption and increasing physician familiarity with FcRn-directed therapy. U.S. biologic exclusivity runs through June 2035, subject to any applicable pediatric extension. [1][2]
What is Rystiggo and how does it work?
Rystiggo is rozanolixizumab-noli, a humanized IgG4 monoclonal antibody that binds the neonatal Fc receptor, or FcRn. FcRn normally protects IgG antibodies from intracellular degradation. By blocking FcRn, Rystiggo increases IgG catabolism and reduces pathogenic autoantibodies associated with gMG.
The FDA approved Rystiggo on June 27, 2023, for adults with gMG who are anti-acetylcholine receptor, or AChR, antibody positive or anti-muscle-specific tyrosine kinase, or MuSK, antibody positive. The drug is administered by subcutaneous infusion once weekly for six weeks. Subsequent treatment cycles are based on clinical evaluation, with the U.S. label providing no fixed minimum interval between cycles. [2]
Rystiggo FDA regulatory profile
| Attribute | Data |
|---|---|
| Active ingredient | Rozanolixizumab-noli |
| Sponsor | UCB, Inc. |
| U.S. application | BLA 761286 |
| FDA approval | June 27, 2023 |
| Initial indication | Adults with generalized myasthenia gravis |
| Eligible antibody populations | Anti-AChR or anti-MuSK positive |
| Administration | Subcutaneous infusion |
| Standard treatment cycle | Six weekly doses |
| Regulatory pathway | Biologics license application |
| U.S. reference | FDA prescribing information and Purple Book |
The pivotal MycarinG study showed improvements in the Myasthenia Gravis Activities of Daily Living score and Quantitative Myasthenia Gravis score compared with placebo. The study enrolled patients with AChR or MuSK antibodies, supporting Rystiggo’s positioning across the two principal serological subgroups. [2][3]
How large is the Rystiggo market?
The commercial market is the growing FcRn inhibitor segment within gMG, rather than the entire myasthenia gravis drug market. The addressable population includes patients with generalized disease who remain symptomatic despite corticosteroids, immunosuppressants, intravenous immunoglobulin, plasma exchange or other targeted treatments.
The principal market drivers are:
- Chronic disease management requiring repeated treatment.
- Preference for targeted immunomodulation over broad immunosuppression.
- Expansion of specialist prescribing beyond refractory patients.
- Greater use in both AChR-positive and MuSK-positive disease.
- Potential label expansion into additional autoimmune diseases.
Rystiggo has a commercial advantage in MuSK-positive disease because the FDA label directly includes both AChR- and MuSK-antibody-positive patients. Vyvgart, by contrast, initially entered the U.S. market with an indication for adults with gMG who are anti-AChR antibody positive. Vyvgart later expanded through the subcutaneous Vyvgart Hytrulo formulation, increasing convenience and competitive pressure.
How does Rystiggo compare with Vyvgart?
| Factor | Rystiggo | Vyvgart | Vyvgart Hytrulo |
|---|---|---|---|
| Active ingredient | Rozanolixizumab-noli | Efgartigimod alfa | Efgartigimod alfa and recombinant human hyaluronidase |
| Mechanism | FcRn antagonist | FcRn antagonist | FcRn antagonist |
| Company | UCB | argenx | argenx |
| U.S. gMG approval | 2023 | 2021 | 2023 |
| Administration | Weekly subcutaneous infusion for six weeks | Intravenous infusion | Subcutaneous injection |
| Antibody coverage | AChR and MuSK | Initially AChR | Based on Vyvgart labeling |
| Treatment pattern | Repeated six-week cycles | Repeated treatment cycles | Repeated treatment cycles |
| Main commercial issue | Infusion logistics and cycle durability | Established first-mover base | Convenience and self-administration potential |
The comparison is clinically nuanced. Rystiggo’s weekly six-dose cycle may fit patients and infusion centers that prefer a defined course. Vyvgart Hytrulo’s subcutaneous delivery may be more attractive where patients and payers prioritize administration convenience. Head-to-head efficacy data are not available, so commercial selection is likely to depend on serology, prior response, administration setting, cycle durability, contracting and local access.
What is Rystiggo’s financial trajectory?
UCB’s reported sales indicate a rapid launch ramp:
| Fiscal year | Rystiggo reported sales | Commercial status |
|---|---|---|
| 2023 | Approximately €14 million | Initial U.S. launch after June approval |
| 2024 | Approximately €174 million | Broadening U.S. uptake and international contribution |
| 2025 outlook | Growth expected from the 2024 base | Dependent on repeat cycles, access and competitive share |
The increase from 2023 to 2024 reflects the transition from launch-stage revenue to a recurring-treatment model. The key economic feature is that patients may receive multiple six-week courses rather than a single treatment episode. That structure can produce substantial annual revenue per treated patient, but it also creates sensitivity to response duration, payer authorization and discontinuation.
Rystiggo is not yet one of UCB’s largest products. Its strategic value is its growth rate and its ability to offset maturity in older neurology products. UCB’s broader portfolio includes Bimzelx, Cimzia, Vimpat, Briviact, Fintepla and Evenity. Rystiggo is positioned as a growth asset alongside Bimzelx rather than as a near-term replacement for UCB’s largest established products. [1]
What could drive Rystiggo sales above the current trajectory?
The strongest revenue catalysts are:
- Higher repeat-cycle rates among initial responders.
- Greater use in earlier lines of gMG treatment.
- Wider reimbursement coverage.
- Growth in MuSK-positive prescribing.
- Additional approvals in autoimmune diseases.
- Simplified administration or delivery options.
- International commercialization in major markets.
The main constraints are treatment cost, infusion-center capacity, payer step edits, competition from Vyvgart Hytrulo and the limited size of the diagnosed gMG population.
When does Rystiggo lose exclusivity?
Rystiggo’s U.S. biologic reference-product exclusivity began on the FDA approval date, June 27, 2023. The statutory 12-year period under the Biologics Price Competition and Innovation Act therefore runs to June 27, 2035, before any pediatric exclusivity extension. [4]
| Exclusivity or protection | Expected date or status |
|---|---|
| U.S. reference-product biologic exclusivity | June 27, 2035 |
| Potential six-month pediatric extension | Could extend to December 27, 2035 if granted |
| U.S. biosimilar filing timing | Generally four years after approval |
| U.S. biosimilar approval timing | Generally not before 12 years after approval |
| Small-molecule Orange Book framework | Not applicable |
| Biologic reference listing | Purple Book framework |
A biosimilar applicant may generally submit an application four years after the reference product’s approval, but FDA approval is generally barred until the 12-year reference-product exclusivity period ends. Patent litigation can delay or shape launch timing after that point.
What patents protect Rystiggo?
Rystiggo is protected through a combination of biologic exclusivity and patent rights covering the antibody, binding characteristics, uses, formulations and manufacturing processes. Because Rystiggo is a biologic, its core protections are not analyzed through the conventional small-molecule Orange Book patent framework.
The principal patent categories are:
- Antibody composition and sequence claims.
- FcRn-binding and blocking claims.
- Treatment of myasthenia gravis.
- Dosing and repeat-cycle regimens.
- Pharmaceutical compositions.
- Cell-line, expression and manufacturing methods.
- Potential combination-treatment claims.
Patent expiry dates depend on the specific U.S. patent, patent-term adjustment, terminal disclaimers, patent-term extension and claim scope. UCB’s biologic exclusivity through 2035 is a separate statutory protection and does not eliminate the relevance of later-expiring formulation, use or manufacturing patents.
What is the Orange Book status of Rystiggo?
Rystiggo does not have the same Orange Book listing structure as a conventional small-molecule drug approved under an NDA. Its principal regulatory reference is the FDA Purple Book, which identifies licensed biological products and reference products relevant to biosimilar competition. [4]
This distinction matters for litigation. A future biosimilar applicant would proceed under the BPCIA patent-exchange process rather than the standard Hatch-Waxman Paragraph IV process used for generic drugs.
Are there Paragraph IV challenges to Rystiggo?
There is no conventional Paragraph IV pathway for Rystiggo because it is approved as a biologic under a BLA. A future competitor would file a biosimilar application under section 351(k) of the Public Health Service Act and could engage in BPCIA patent litigation.
No publicly established Rystiggo biosimilar litigation materially affects the product’s current U.S. commercial position. The earliest statutory biosimilar approval window begins in June 2035, although patent disputes could become active earlier through the BPCIA process.
What litigation and settlement risks affect Rystiggo?
The current commercial risk is competitive rather than litigation-driven. Key future disputes could involve:
- Whether a biosimilar infringes antibody composition patents.
- Whether dosing patents cover repeated treatment cycles.
- Whether formulation patents survive validity challenges.
- Whether manufacturing claims are difficult to design around.
- Whether UCB pursues a settlement that permits an agreed launch date.
- Whether a competitor challenges patents through inter partes review or district-court proceedings.
No major publicly reported settlement agreement or active patent case has established an earlier Rystiggo biosimilar launch date. The absence of current litigation does not remove long-term patent risk, but it leaves the product’s 2035 biologic-exclusivity date as the clearest public timing marker.
What manufacturing and intellectual-property barriers protect Rystiggo?
Manufacturing complexity provides an additional barrier beyond patents. A biosimilar developer must demonstrate analytical similarity, comparable pharmacokinetics, immunogenicity and, where appropriate, pharmacodynamic activity. Monoclonal antibody production also requires validated cell lines, upstream and downstream processes, comparability controls and commercial-scale quality systems.
Rystiggo’s subcutaneous infusion presentation may create formulation and device-development considerations. A competitor seeking a different delivery format could avoid some formulation claims but would still need to establish an acceptable biosimilar or interchangeable product strategy.
Manufacturing barriers are meaningful but not permanent. Large biosimilar companies and contract manufacturers have established capabilities for antibody development. The more durable protection is likely to come from the combined effect of biologic exclusivity, patent layering, regulatory complexity and commercial relationships with neuromuscular specialists.
What licensing deals support Rystiggo?
Rystiggo is an internally developed UCB product rather than a product widely associated with a major external licensing transaction. UCB controls the principal commercial and development strategy. No major third-party licensing deal is required to explain the product’s current market position.
Commercial economics may still involve regional distribution, reimbursement services, specialty pharmacy arrangements and infusion-provider contracts. Those arrangements are generally less important to exclusivity than UCB’s BLA, patent estate and manufacturing controls.
What generic or biosimilar entry risks exist?
Near-term generic entry risk is effectively absent. The relevant long-term threat is biosimilar entry after the statutory reference-product exclusivity period and resolution of patent barriers.
| Risk period | Entry assessment |
|---|---|
| 2025-2030 | Low biosimilar entry risk; commercial competition is the primary threat |
| 2030-2034 | Patent preparation and possible BPCIA activity become more relevant |
| 2035 | Earliest statutory U.S. biosimilar approval window |
| After 2035 | Entry depends on patent validity, settlements, interchangeability and manufacturing readiness |
The larger near-term risk is share erosion within the FcRn class. Vyvgart Hytrulo may compete for patients who prefer subcutaneous administration. Additional FcRn antagonists could increase payer leverage and reduce net pricing even before biosimilar competition begins.
How strong is the Rystiggo commercial and patent estate?
The estate is commercially strong through the mid-2030s because it combines:
- A 12-year U.S. biologic exclusivity period.
- Patent protection across composition, use, formulation and manufacturing categories.
- A differentiated label covering AChR- and MuSK-positive gMG.
- Repeat-course treatment economics.
- UCB’s established neurology and immunology infrastructure.
The principal weakness is class concentration. Rystiggo and Vyvgart target the same FcRn mechanism, so clinical differentiation may be limited without head-to-head evidence. Administration burden and payer positioning can therefore influence market share as much as molecular characteristics.
Key Takeaways
- Rystiggo is UCB’s FcRn antagonist for adults with AChR- or MuSK-positive generalized myasthenia gravis.
- UCB’s reported sales increased from approximately €14 million in 2023 to approximately €174 million in 2024.
- The commercial model benefits from repeat six-week treatment cycles, but revenue depends on clinical durability and payer reauthorization.
- The main competitor is argenx’s Vyvgart franchise, particularly subcutaneous Vyvgart Hytrulo.
- Rystiggo’s U.S. biologic exclusivity runs through June 27, 2035, before any pediatric extension.
- Paragraph IV litigation does not apply; future competition will use the BPCIA biosimilar pathway.
- No major public Rystiggo biosimilar litigation or settlement currently establishes an earlier U.S. entry date.
- Near-term risk is competitive share loss and pricing pressure, not generic substitution.
- Patent strength depends on the combined protection of antibody, use, formulation and manufacturing claims.
FAQs
Is Rystiggo a blockbuster drug?
Rystiggo had not reached blockbuster scale based on UCB’s reported 2024 sales of approximately €174 million. Its growth rate is strong, and blockbuster potential depends on repeat treatment, international penetration and additional indications.
Is Rystiggo better than Vyvgart?
There is no definitive head-to-head evidence establishing superiority. Rystiggo has a label covering both AChR- and MuSK-positive gMG, while Vyvgart benefits from earlier market entry and a subcutaneous formulation.
Can Rystiggo be replaced by a generic?
No conventional generic substitution is expected. Rystiggo is a biologic, so future competition would come from biosimilars under the BPCIA pathway.
What is the biggest commercial risk for Rystiggo?
The biggest risk is loss of share to competing FcRn therapies, especially Vyvgart Hytrulo, combined with payer pressure on treatment sequencing and repeat-cycle authorization.
Does Rystiggo have orphan-drug protection?
Rystiggo was developed for a rare disease population, but orphan-drug designation and exclusivity must be assessed separately from the product’s biologic exclusivity and patent rights. The principal U.S. timing protection publicly relevant to biosimilar entry is the 12-year BPCIA reference-product exclusivity period.
References
-
UCB. (2025). Annual report 2024. UCB S.A.
-
U.S. Food and Drug Administration. (2023). Rystiggo prescribing information: Rozanolixizumab-noli injection.
-
Howard, J. F., Bril, V., Vu, T., et al. (2023). Safety, efficacy, and tolerability of rozanolixizumab in generalized myasthenia gravis: The MycarinG randomized clinical trial. Neurology, 100(14), e1427-e1437.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
More… ↓
